Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIC100 CAR T Cells in Advanced Thyroid Cancer
NCT04420754Phase 1Active, not recruiting
- Sponsor
- AffyImmune Therapeutics
- Start
- Sep 2020
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of AIC100 in anaplastic thyroid cancer (ATC) and thyroid cancer (7 cohorts), sponsored by AffyImmune Therapeutics. Primary endpoints: Incidence of overall Grade >=3 Adverse Events and Serious Adverse Events, Recommended Phase 2 Dose and 1 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
AIC100
03
Conditions
anaplastic thyroid cancer (ATC)thyroid cancer
Beyond the preview
Go deeper on NCT04420754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04420754.